AVACTA GROUP PLC LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC ...

Based on the company’s proprietary Peptide Drug Conjugate (PDC) platform, OPD5 is a follow-on molecule to Oncopeptides’ flagship drug melflufen (branded in Europe as Pepaxti) with a potentially ...

AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have ...

LONDON and PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful ...

LONDON and PHILADELPHIA - March 26, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads ...

For more details see announcement from 07 March 2025 here. AVA6103, a pre|CISION ®-enabled PDC comprised of the pre|CISION peptide linked to the potent topo I inhibitor exatecan, continues ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further ...

LONDON AND PHILADELPHIA - March 31, 2025 Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti ...